全文获取类型
收费全文 | 20056篇 |
免费 | 1391篇 |
国内免费 | 56篇 |
专业分类
耳鼻咽喉 | 125篇 |
儿科学 | 427篇 |
妇产科学 | 268篇 |
基础医学 | 2671篇 |
口腔科学 | 326篇 |
临床医学 | 2517篇 |
内科学 | 3479篇 |
皮肤病学 | 198篇 |
神经病学 | 1778篇 |
特种医学 | 705篇 |
外科学 | 2806篇 |
综合类 | 221篇 |
一般理论 | 28篇 |
预防医学 | 2601篇 |
眼科学 | 427篇 |
药学 | 1590篇 |
中国医学 | 35篇 |
肿瘤学 | 1301篇 |
出版年
2023年 | 123篇 |
2022年 | 76篇 |
2021年 | 435篇 |
2020年 | 308篇 |
2019年 | 437篇 |
2018年 | 513篇 |
2017年 | 390篇 |
2016年 | 429篇 |
2015年 | 580篇 |
2014年 | 742篇 |
2013年 | 969篇 |
2012年 | 1638篇 |
2011年 | 1667篇 |
2010年 | 949篇 |
2009年 | 887篇 |
2008年 | 1456篇 |
2007年 | 1598篇 |
2006年 | 1448篇 |
2005年 | 1445篇 |
2004年 | 1411篇 |
2003年 | 1329篇 |
2002年 | 1148篇 |
2001年 | 138篇 |
2000年 | 105篇 |
1999年 | 156篇 |
1998年 | 192篇 |
1997年 | 131篇 |
1996年 | 96篇 |
1995年 | 97篇 |
1994年 | 106篇 |
1993年 | 85篇 |
1992年 | 46篇 |
1991年 | 43篇 |
1990年 | 28篇 |
1989年 | 32篇 |
1988年 | 22篇 |
1987年 | 30篇 |
1986年 | 25篇 |
1985年 | 23篇 |
1984年 | 24篇 |
1983年 | 25篇 |
1982年 | 22篇 |
1981年 | 25篇 |
1980年 | 20篇 |
1979年 | 4篇 |
1978年 | 9篇 |
1977年 | 7篇 |
1976年 | 13篇 |
1975年 | 3篇 |
1961年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
3.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
4.
5.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
6.
Leonie Konczalla Daniel R. Perez Nadine Wenzel Gerrit Wolters-Eisfeld Clarissa Klemp Johanna Lüddeke Annika Wolski Dirk Landschulze Chris Meier Anika Buchholz Dichao Yao Bianca T. Hofmann Julia K. Graß Sarah L. Spriestersbach Katharina Grupp Udo Schumacher Christian Betzel Svetlana Kapis Theresa Nuguid Pablo Steinberg Klaus Püschel Guido Sauter Maximillian Bockhorn Faik G. Uzunoglu Jakob R. Izbicki Cenap Güngör Alexander T. El Gammal 《International journal of cancer. Journal international du cancer》2020,146(6):1618-1630
MALT1 is a key mediator of NF-κB signaling and a main driver of B-cell lymphomas. Remarkably, MALT1 is expressed in the majority of pancreatic ductal adenocarcinomas (PDACs) as well, but absent from normal exocrine pancreatic tissue. Following, MALT1 shows off to be a specific target in cancer cells of PDAC without affecting regular pancreatic cells. Therefore, we studied the impact of pharmacological MALT1 inhibition in pancreatic cancer and showed promising effects on tumor progression. Mepazine (Mep), a phenothiazine derivative, is a known potent MALT1 inhibitor. Newly, we described that biperiden (Bip) is a potent MALT1 inhibitor with even less pharmacological side effects. Thus, Bip is a promising drug leading to reduced proliferation and increased apoptosis in PDAC cells in vitro and in vivo. By compromising MALT1 activity, nuclear translocation of c-Rel is prevented. c-Rel is critical for NF-κB-dependent inhibition of apoptosis. Hence, off-label use of Bip or Mep represents a promising new therapeutic approach to PDAC treatment. Regularly, the Anticholinergicum Bip is used to treat neurological side effects of Phenothiazines, like extrapyramidal symptoms. 相似文献
7.
Chris G. McMahon 《The journal of sexual medicine》2019,16(8):1125-1127
8.
9.
10.
Turnbull Chris D. Stockley James A. Madathil Shyam Huq Syed S. A. Cooper Brendan G. Ali Asad Wharton Simon Stradling John R. Heitmar Rebekka 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(7):2129-2139
Graefe's Archive for Clinical and Experimental Ophthalmology - Retinal microvascular endothelial dysfunction is thought to be of importance in the development of ocular vascular diseases.... 相似文献